BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative:, Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol 2020;73:1170-218. [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 381] [Cited by in F6Publishing: 371] [Article Influence: 127.0] [Reference Citation Analysis]
Number Citing Articles
1 Wedemeyer H, Tergast TL, Lazarus JV, Razavi H, Bakoyannis K, Baptista-Leite R, Bartoli M, Bruggmann P, Buşoi CS, Buti M, Carballo M, Castera L, Colombo M, Coutinho RS, Dadon Y, Esmat G, Esteban R, Farran JC, Gillyon-Powell M, Goldberg D, Hutchinson S, Janssen HLA, Kalamitsis G, Kondili LA, Lambert JS, Marinho RT, Maticic M, Patricello A, Peck-Radosavljevic M, Pol S, Poljak M, Pop C, Sokol T, Sypsa V, Tözün N, Younossi Z, Aghemo A, Papatheodoridis GV, Hatzakis A. Securing wider EU commitment to the elimination of hepatitis C virus. Liver Int 2023;43:276-91. [PMID: 36196744 DOI: 10.1111/liv.15446] [Reference Citation Analysis]
2 Durantel D. Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow! Antiviral Res 2023;210:105515. [PMID: 36603773 DOI: 10.1016/j.antiviral.2022.105515] [Reference Citation Analysis]
3 Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, Su PY, Kao WY, Tsai MC, Tung HD, Cheng HT, Lee FJ, Huang CS, Huang KJ, Shih YL, Yang SS, Wu JH, Lai HC, Fang YJ, Chen PY, Hwang JJ, Tseng CW, Su WW, Chang CC, Lee PL, Chen JJ, Chang CY, Hsieh TY, Chang CH, Huang YJ, Kao JH. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatol Int 2023. [PMID: 36701081 DOI: 10.1007/s12072-022-10475-9] [Reference Citation Analysis]
4 Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Jiménez-Sousa MA, Ryan P, Martínez I, Fernández-Rodríguez A, Resino S. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis. J Clin Microbiol 2023;61:e0133122. [PMID: 36537787 DOI: 10.1128/jcm.01331-22] [Reference Citation Analysis]
5 Kuznetsov NI, Moiseeva IE. Modern principles of etiotropic therapy for chronic hepatitis B and C. Russian Family Doctor 2023;26:7-15. [DOI: 10.17816/rfd112383] [Reference Citation Analysis]
6 Jessica HB, Carson J, Scott M, Patricia C, Nelson R, Helen VG, Phillip R, Hanson J, Robert M, Matthews G, Dore GJ, Martinello M; REACH-C study group. Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C). J Viral Hepat 2023. [PMID: 36651627 DOI: 10.1111/jvh.13803] [Reference Citation Analysis]
7 Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. Dig Liver Dis 2023:S1590-8658(22)00860-X. [PMID: 36646527 DOI: 10.1016/j.dld.2022.12.014] [Reference Citation Analysis]
8 Conway Morris A, Smielewska A. Viral infections in critical care: a narrative review. Anaesthesia 2023. [PMID: 36633460 DOI: 10.1111/anae.15946] [Reference Citation Analysis]
9 Ferreira J, Oliveira M, Bicho M, Serejo F. Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment. Int J Mol Sci 2023;24. [PMID: 36674897 DOI: 10.3390/ijms24021380] [Reference Citation Analysis]
10 Ciancio A, Ribaldone DG, Spertino M, Risso A, Ferrarotti D, Caviglia GP, Carucci P, Gaia S, Rolle E, Sacco M, Saracco GM. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. Biomedicines 2023;11. [PMID: 36672675 DOI: 10.3390/biomedicines11010166] [Reference Citation Analysis]
11 Dong H, Xue C, Zheng Y, Zhang X, Hu Z, Lu X, Yu Y, Li J, Tan K, Cui H. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. J Oncol 2023;2023:2525903. [PMID: 36647390 DOI: 10.1155/2023/2525903] [Reference Citation Analysis]
12 Mourik K, Boers SA, van Rijn AL, Thijssen JCP, Wessels E, Claas ECJ. Clinical performance of two new, fully integrated molecular platforms used for HIV-1, HBV and HCV viral load analysis, the NeuMoDx 288 and the Alinity m. J Clin Virol 2023;160:105376. [PMID: 36640531 DOI: 10.1016/j.jcv.2022.105376] [Reference Citation Analysis]
13 Seear K, Mulcahy S, Kagan D, Lenton E, Fraser S, Valentine K, Farrugia A. Complicating cure: How Australian criminal law shapes imagined post-hepatitis C futures. Sociol Health Illn 2023;45:179-95. [PMID: 36254737 DOI: 10.1111/1467-9566.13562] [Reference Citation Analysis]
14 Burger D, Aktas H, de Knegt R. Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir. Journal of Hepatology 2023. [DOI: 10.1016/j.jhep.2023.01.015] [Reference Citation Analysis]
15 Gusev DA, Zhdanov KV, Kozlov KV, Vinogradova TN, Kopot MY, Sukachev VS, Zhabrov SS, Kizhlo SN, Romanova SY, Musatov VB, Tyurenkova NV, Vlasova YA, Kolpashchikova EY, Fedorov PN, Minin PV, Korneeva TS. Real-world effectiveness and safety of pan-genotypic antiviral therapy for chronic HCV-infection: data from three clinical centers in St. Petersburg. jour 2023;14:60-68. [DOI: 10.22625/2072-6732-2022-14-5-60-68] [Reference Citation Analysis]
16 Ma L, Liu S, Xing H, Jin Z. Research progress on short-term prognosis of acute-on-chronic liver failure. Expert Rev Gastroenterol Hepatol 2023;17:45-57. [PMID: 36597928 DOI: 10.1080/17474124.2023.2165063] [Reference Citation Analysis]
17 Isfordink CJ, van Erpecum KJ, Fischer K, van der Valk PR, van Vulpen LFD, Schutgens REG, Arends JE, Mauser-Bunschoten EP. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders. Haemophilia 2023;29:106-14. [PMID: 36184751 DOI: 10.1111/hae.14668] [Reference Citation Analysis]
18 Zou Y, Yue M, Jia L, Wang Y, Chen H, Wang Y, Zhang M, Feng Y, Yu R, Yang S, Huang P. Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR. J Hepatocell Carcinoma 2022;9:1433-43. [PMID: 36606114 DOI: 10.2147/JHC.S389874] [Reference Citation Analysis]
19 Kozuka R, Tamori A, Enomoto M, Muto-Yukawa Y, Odagiri N, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Kawada N. Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort. J Viral Hepat 2022. [PMID: 36583600 DOI: 10.1111/jvh.13795] [Reference Citation Analysis]
20 Krekulová L, Damajka T, Krumphanslová Z, Řehák V. Pilot Outreach Program in Remedis-The Promising Step toward HCV Elimination among People Who Inject Drugs. Int J Environ Res Public Health 2022;20. [PMID: 36612821 DOI: 10.3390/ijerph20010501] [Reference Citation Analysis]
21 Songtanin B, Nugent K. Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection. Biology (Basel) 2022;12. [PMID: 36671716 DOI: 10.3390/biology12010023] [Reference Citation Analysis]
22 Obi S, Kanda M, Ooka Y, Ohyama H, Yokouchi R, Sato N, Mochizuki H, Omata M. The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV.. [DOI: 10.21203/rs.3.rs-2364089/v1] [Reference Citation Analysis]
23 Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS One 2022;17:e0279416. [PMID: 36542633 DOI: 10.1371/journal.pone.0279416] [Reference Citation Analysis]
24 Nasr T, Aboshanab AM, Mpekoulis G, Drakopoulos A, Vassilaki N, Zoidis G, Abouzid KAM, Zaghary W. Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. Viruses 2022;14. [PMID: 36560772 DOI: 10.3390/v14122767] [Reference Citation Analysis]
25 Bregenzer A, Krismer C, Wendel S, Roser P, Fux CA. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study. Swiss Med Wkly 2022;152:40009. [PMID: 36509421 DOI: 10.57187/smw.2022.40009] [Reference Citation Analysis]
26 Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2022;2022:676-87. [PMID: 36485086 DOI: 10.1182/hematology.2022000362] [Reference Citation Analysis]
27 Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396 [DOI: 10.3748/wjg.v28.i45.6380] [Reference Citation Analysis]
28 Meskina ER, Galkina LA, Tselipanova EE, Odinaeva ND. Hepatitis C virus care cascade for children in Moscow Region. Journal of microbiology, epidemiology and immunobiology 2022;99:525-539. [DOI: 10.36233/0372-9311-330] [Reference Citation Analysis]
29 Pimenov N, Kostyushev D, Komarova S, Fomicheva A, Urtikov A, Belaia O, Umbetova K, Darvina O, Tsapkova N, Chulanov V. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens 2022;11. [PMID: 36558817 DOI: 10.3390/pathogens11121482] [Reference Citation Analysis]
30 Donaldson SR, Radley A, Dillon JF. Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world. Subst Abuse Treat Prev Policy 2022;17:45. [DOI: 10.1186/s13011-022-00475-1] [Reference Citation Analysis]
31 Maasoumy B, Ingiliz P, Spinner CD, Cordes C, Stellbrink H, Schulze zur Wiesch J, Schneeweiß SM, Deterding K, Müller T, Kahlhöfer J, Dörge P, von Karpowitz M, Manns MP, Wedemeyer H, Cornberg M. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100650] [Reference Citation Analysis]
32 Esteban R, Domínguez-Hernández R, Martín-Escudero V, Casado MÁ. Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain. PLoS One 2022;17:e0278544. [PMID: 36454996 DOI: 10.1371/journal.pone.0278544] [Reference Citation Analysis]
33 Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-nwulia O, Page K. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. The Lancet Gastroenterology & Hepatology 2022;7:1112-1127. [DOI: 10.1016/s2468-1253(22)00275-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int 2022;102:S129-205. [PMID: 36410841 DOI: 10.1016/j.kint.2022.07.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chen GJ, Sun HY, Chang SY, Su LH, Chen YT, Hsieh SM, Liu WD, Sheng WH, Huang YS, Lin KY, Su YC, Liu WC, Hung CC. Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6. Emerg Microbes Infect 2022;11:1227-35. [PMID: 35412439 DOI: 10.1080/22221751.2022.2065933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Pol S. Epatite virale C. EMC - AKOS - Trattato di Medicina 2022;24:1-9. [DOI: 10.1016/s1634-7358(22)47256-1] [Reference Citation Analysis]
37 Grosse S, Tahri A, Raboisson P, Houpis Y, Stoops B, Jacoby E, Neefs J, Van Loock M, Goethals O, Geluykens P, Bonfanti J, Jonckers THM. From Oxetane to Thietane: Extending the Antiviral Spectrum of 2′-Spirocyclic Uridines by Substituting Oxygen with Sulfur. ACS Med Chem Lett 2022. [DOI: 10.1021/acsmedchemlett.2c00372] [Reference Citation Analysis]
38 Borghi C, Ciancio A, Gentile I, Perrone Filardi P, Pasqualetti P, Brillanti S. Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project. J Clin Med 2022;11. [PMID: 36498521 DOI: 10.3390/jcm11236946] [Reference Citation Analysis]
39 van der Pluijm RW, Smits LP, Rebers SP, Schinkel J, van der Valk M. Unmasking a hepatitis C genotype 3a/1b dual infection in an individual treated with elbasvir/grazoprevir. J Hepatol 2022:S0168-8278(22)03310-4. [PMID: 36435298 DOI: 10.1016/j.jhep.2022.11.016] [Reference Citation Analysis]
40 Suan MAM, Chan HK, Sem X, Shilton S, Hassan MRA. Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection. Sci Rep 2022;12:20153. [PMID: 36418369 DOI: 10.1038/s41598-022-24612-9] [Reference Citation Analysis]
41 Wong YJ, Sharma S, Tosetti G, Xiaolong QI, Primignani M. Can we apply Baveno-VII criteria in our real-world practice? Clin Mol Hepatol 2022. [PMID: 36417891 DOI: 10.3350/cmh.2022.0408] [Reference Citation Analysis]
42 Dema E, Stander J, Cortina-Borja M, Thorne C, Bailey H. Estimating the number of livebirths to Hepatitis C seropositive women in England in 2013 and 2018 using Bayesian modelling. PLoS One 2022;17:e0274389. [PMID: 36409689 DOI: 10.1371/journal.pone.0274389] [Reference Citation Analysis]
43 Greeviroj P, Lertussavavivat T, Thongsricome T, Takkavatakarn K, Phannajit J, Avihingsanon Y, Praditpornsilpa K, Eiam-ong S, Susantitaphong P. The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis. J Nephrol 2022. [DOI: 10.1007/s40620-022-01483-x] [Reference Citation Analysis]
44 Pham LV, Velázquez-moctezuma R, Fahnøe U, Collignon L, Bajpai P, Sølund C, Weis N, Holmbeck K, Prentoe J, Bukh J. Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization. Viruses 2022;14:2527. [DOI: 10.3390/v14112527] [Reference Citation Analysis]
45 Kim BK. How to Optimize the Care Cascade of Hepatitis C Virus Infection. Gut and Liver 2022;16:809-810. [DOI: 10.5009/gnl220452] [Reference Citation Analysis]
46 Abo-zeid Y, Amer A, Bakkar MR, El-houssieny B, Sakran W. Antimicrobial Activity of Azithromycin Encapsulated into PLGA NPs: A Potential Strategy to Overcome Efflux Resistance. Antibiotics 2022;11:1623. [DOI: 10.3390/antibiotics11111623] [Reference Citation Analysis]
47 Sabry N, Kamel AM, Cordie A, Esmat G. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2145883] [Reference Citation Analysis]
48 Wedemeyer H, Di Marco V, Garcia-retortillo M, Teti E, Fraser C, Morano Amado LE, Rodriguez-tajes S, Acosta-lópez S, O’loan J, Milella M, Buti M, Guerra-veloz MF, Ramji A, Fenech M, Martins A, Borgia SM, Vanstraelen K, Mertens M, Hernández C, Ntalla I, Ramroth H, Milligan S. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders. Viruses 2022;14:2493. [DOI: 10.3390/v14112493] [Reference Citation Analysis]
49 Sulima DL, Suleymanova SS, Yakovlev AA, Koryagin VN, Rassokhin VV. Virological failures of primary interferon-free therapy in patients with chronic HCV RNA viremia and successful repeated interferon-free therapy. VIČ-infekc immunosupr 2022;14:100-109. [DOI: 10.22328/2077-9828-2022-14-3-100-109] [Reference Citation Analysis]
50 Liu C, Peng C, Liu C, Chen C, Lo C, Tseng K, Su P, Kao W, Tsai M, Tung H, Cheng H, Lee F, Huang C, Huang K, Shih Y, Yang S, Wu J, Lai H, Fang Y, Chen P, Hwang J, Tseng C, Su W, Chang C, Lee P, Chen J, Chang C, Hsieh T, Chang C, Huang Y, Kao J. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.. [DOI: 10.21203/rs.3.rs-2215740/v1] [Reference Citation Analysis]
51 Guerra-Veloz MF, Han K, Oakes K, Robertson D, Mohamed A, Cannon M, Barnabas A, Shah S, Halford R, Dusheiko G, Agarwal K. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England. Am J Gastroenterol 2022. [PMID: 36191276 DOI: 10.14309/ajg.0000000000002041] [Reference Citation Analysis]
52 Burgui C, San Miguel R, Goñi-esarte S, Juanbeltz R, Úriz-otano JI, Reparaz J, Sarobe M, Zozaya JM, Castilla J. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal. Postgraduate Medicine 2022. [DOI: 10.1080/00325481.2022.2141499] [Reference Citation Analysis]
53 Chernov VS, Kozlov KV, Patlusov EP. Epidemiological features of chronic hepatitis C in servicemen of the national guard in the Ural federal district. jour 2022;21:74-80. [DOI: 10.52420/2071-5943-2022-21-5-74-80] [Reference Citation Analysis]
54 Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang. Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China. Infect Drug Resist 2022;15. [PMID: 36353379 DOI: 10.2147/IDR.S385071] [Reference Citation Analysis]
55 Aranda EB, Fernández Marcos C, Puebla Maestu A, Gozalo Marín V, Vinuesa Campo R, Calvo Simal S, Gómez Camarero J. Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up. Gastroenterología y Hepatología (English Edition) 2022. [DOI: 10.1016/j.gastre.2022.02.005] [Reference Citation Analysis]
56 Pol S. Hepatitis vírica C. EMC - Tratado de Medicina 2022. [DOI: 10.1016/s1636-5410(22)47172-8] [Reference Citation Analysis]
57 Klang E, Soffer S, Alper L, Shimon O, Barash Y, Davidov Y, Likhter M, Cohen‐ezra O, Ben Yakov G, Ben‐ari Z. Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.805] [Reference Citation Analysis]
58 Younossi ZM, Yu ML, El-Kassas M, Esmat G, Castellanos Fernández MI, Buti M, Papatheodoridis G, Yilmaz Y, Isakov V, Duseja A, Méndez-Sánchez N, Hamid S, Gordon SC, Romero-Gómez M, Chan WK, Ong JP, Younossi I, Lam B, Ziayee M, Nader F, Racila A, Henry L, Stepanova M; Global NASH Council™. Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry. J Viral Hepat 2022;29:1015-25. [PMID: 36036096 DOI: 10.1111/jvh.13741] [Reference Citation Analysis]
59 Saeed H, Cano EJ, Khan MQ, Yetmar ZA, Smith B, Rizza SA, Badley AD, Mahmood M, Leise MD, Cummins NW. Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era. Life 2022;12:1755. [DOI: 10.3390/life12111755] [Reference Citation Analysis]
60 Franzè MS, Filomia R, Caccamo G, Pitrone C, Alibrandi A, Saitta C, Caspanello AR, Asero C, Arcadi V, Raimondo G, Cacciola I. Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. J Pers Med 2022;12. [PMID: 36579534 DOI: 10.3390/jpm12111794] [Reference Citation Analysis]
61 MOHAMMAD MAHDI MAJZOOBI, SEPIDEH NAMDAR, ROYA NAJAFI-VOSOUGH, ALI ABBAS HAJILOOI, HOSSEIN MAHJUB. Prediction of Hepatitis disease using ensemble learning methods. J Prev Med Hyg 2022;63. [PMID: 36415304 DOI: 10.15167/2421-4248/jpmh2022.63.3.2515] [Reference Citation Analysis]
62 Peschel G, Grimm J, Müller M, Höring M, Krautbauer S, Weigand K, Liebisch G, Buechler C. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection. Lipids Health Dis 2022;21:106. [PMID: 36280840 DOI: 10.1186/s12944-022-01715-w] [Reference Citation Analysis]
63 Wong TH, Ho CM, Hsu HH, Wu YM, Ho MC, Lee PH, Hu RH. Delayed Hepatocellular Carcinoma Recurrence After Liver Transplantation: Comprehensive Clinical Characterization of Case Series. J Hepatocell Carcinoma 2022;9:1081-91. [PMID: 36275405 DOI: 10.2147/JHC.S383474] [Reference Citation Analysis]
64 Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J. Virus-Associated Nephropathies: A Narrative Review. Int J Mol Sci 2022;23:12014. [PMID: 36233315 DOI: 10.3390/ijms231912014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Spanoudaki A, Papadopoulos N, Trifylli EM, Koustas E, Vasileiadi S, Deutsch M. Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management. J Multidiscip Healthc 2022;15:2301-9. [PMID: 36247180 DOI: 10.2147/JMDH.S363177] [Reference Citation Analysis]
66 Campollo O, Amaya G, McCormick PA. Milestones in the discovery of hepatitis C. World J Gastroenterol 2022; 28(37): 5395-5402 [DOI: 10.3748/wjg.v28.i37.5395] [Reference Citation Analysis]
67 Mak LY, Beasley I, Kennedy PTF. Chronic Viral Hepatitis in Elite Athletes: Approaches to Risk Assessment, Prevention and Management. Sports Med Open 2022;8:123. [PMID: 36192563 DOI: 10.1186/s40798-022-00517-9] [Reference Citation Analysis]
68 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol 2022;77:1161-97. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
69 Ebada HE, Montasser MF, Abdelghaffar MF, Bahaa MM, Elbaset HSA, Sakr MA, Dabbous HM, Montasser IF, Hassan MS, Aboelmaaty ME, Elmeteini MS. Ascites post-living donor liver transplantation: Risk factors and outcome. Journal of Liver Transplantation 2022;8:100112. [DOI: 10.1016/j.liver.2022.100112] [Reference Citation Analysis]
70 Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez-Sousa MA, Fernández-Rodríguez A, Martínez I, Resino S. Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2022;56:1224-34. [PMID: 36031747 DOI: 10.1111/apt.17198] [Reference Citation Analysis]
71 Karimi-Sari H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. J Hepatol 2022;77:1215-7. [PMID: 35798132 DOI: 10.1016/j.jhep.2022.06.024] [Reference Citation Analysis]
72 Calleja Panero JL, de la Poza G, Hidalgo L, Aguilera Sancho-tello MV, Torras X, Santos de Lamadrid R, Maté C, Sánchez Antolín G. Patient journey of individuals tested for HCV in Spain: LiverTAI, a retrospective analysis of EHRs through natural language processing. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.10.012] [Reference Citation Analysis]
73 Ramadan MS, Boccia F, Moretto SM, De Gregorio F, Gagliardi M, Iossa D, Durante-mangoni E, Zampino R. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. JCM 2022;11:5781. [DOI: 10.3390/jcm11195781] [Reference Citation Analysis]
74 Su P, Chang T, Tung S, Wei K, Shen C, Hsieh Y, Chen W, Chen Y, Chen C, Yen C, Xu H, Tung W, Chang K. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir. Adv in Digestive Medicine 2022. [DOI: 10.1002/aid2.13336] [Reference Citation Analysis]
75 Sayaf K, Gabbia D, Russo FP, De Martin S. The Role of Sex in Acute and Chronic Liver Damage. IJMS 2022;23:10654. [DOI: 10.3390/ijms231810654] [Reference Citation Analysis]
76 Pinto L, Balbi E, Halpern M, Carius L, Roma J, Cardoso SW, Grinsztejn B, Veloso VG, Pacheco L, Perazzo H. Effectiveness of Direct-acting Agents After Liver Transplantation and Regression of Biomarkers Post-HCV Treatment: A Real-life Study in Rio de Janeiro. Arch Med Res 2022:S0188-4409(22)00104-7. [PMID: 36114037 DOI: 10.1016/j.arcmed.2022.09.001] [Reference Citation Analysis]
77 Tang KT, Lin CC, Chen YH, Liao TL, Chen DY, Yang SS, Chen CC. Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C. J Clin Med 2022;11:5327. [PMID: 36142974 DOI: 10.3390/jcm11185327] [Reference Citation Analysis]
78 Majchrzak M, Bronner K, Laperche S, Riester E, Bakker E, Bollhagen R, Klinkicht M, Vermeulen M, Schmidt M. Multicenter performance evaluation of the Elecsys HCV Duo immunoassay. J Clin Virol 2022;156:105293. [PMID: 36126395 DOI: 10.1016/j.jcv.2022.105293] [Reference Citation Analysis]
79 Leiva RA, Bergersen BM, Finbråten AK, Sandvei PK, Simonsen Ø, Rosseland CM, Hagen K, Young L, Roberts RS, Mikkelsen Y, Singh R, Lagging M, Dalgard O. High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway. Scand J Gastroenterol 2022;:1-5. [PMID: 36063075 DOI: 10.1080/00365521.2022.2118555] [Reference Citation Analysis]
80 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Gómez-Gallego F, Corral O, Soriano V. Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. J Viral Hepat 2022;29:777-84. [PMID: 35643914 DOI: 10.1111/jvh.13708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Hsu WF, Lai HC, Chuang PH, Su WP, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY. Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents. J Viral Hepat 2022;29:785-94. [PMID: 35657121 DOI: 10.1111/jvh.13715] [Reference Citation Analysis]
82 Höring M, Peschel G, Grimm J, Krautbauer S, Müller M, Weigand K, Liebisch G, Buechler C. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection. IJMS 2022;23:9806. [DOI: 10.3390/ijms23179806] [Reference Citation Analysis]
83 Shin SH, Park SH. Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2022;80:51-59. [DOI: 10.4166/kjg.2022.096] [Reference Citation Analysis]
84 Santarone S, Angelini S, Natale A, Vaddinelli D, Spadano R, Casciani P, Papola F, Di Lembo E, Iannetti G, Di Bartolomeo P. Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major. Bone Marrow Transplant 2022. [PMID: 36002533 DOI: 10.1038/s41409-022-01786-4] [Reference Citation Analysis]
85 Lu Y, Lu C, Chen C, Hsieh Y, Tung S, Chen Y, Yen C, Tung W, Chang K, Chen W, Lu S, Hung C, Chang T. Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PLoS ONE 2022;17:e0272567. [DOI: 10.1371/journal.pone.0272567] [Reference Citation Analysis]
86 Sharrock KC, Noori T, Axelsson M, Buti M, Diaz A, Fursa O, Hendrickx G, James C, Klavs I, Korenjak M, Maticic M, Mozalevskis A, Peters L, Rigoni R, Rosinska M, Ruutel K, Schatz E, Seyler T, Veldhuijzen I, Duffell E. Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. PLOS Glob Public Health 2022;2:e0000841. [DOI: 10.1371/journal.pgph.0000841] [Reference Citation Analysis]
87 Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. World J Gastroenterol 2022; 28(30): 4182-4200 [DOI: 10.3748/wjg.v28.i30.4182] [Reference Citation Analysis]
88 Schorr O, Blach S, Thurnheer C, Ruis C, Dufour J. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic. PLoS ONE 2022;17:e0272518. [DOI: 10.1371/journal.pone.0272518] [Reference Citation Analysis]
89 García-crespo C, Vázquez-sirvent L, Somovilla P, Soria ME, Gallego I, de Ávila AI, Martínez-gonzález B, Durán-pastor A, Domingo E, Perales C. Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture. Front Microbiol 2022;13:960676. [DOI: 10.3389/fmicb.2022.960676] [Reference Citation Analysis]
90 Armandi A, Rosso C, Troshina G, Pérez Diaz Del Campo N, Marinoni C, Nicolosi A, Caviglia GP, Saracco GM, Bugianesi E, Ciancio A. Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals. Biology 2022;11:1160. [DOI: 10.3390/biology11081160] [Reference Citation Analysis]
91 Padilla-machaca PM, Luna-victoria E, Cabrera A, Gómez-de la Torre J, Galloso R, Montes P. Chronic hepatitis C in hemodialysis patients: Prevalence and liver fibrosis impact in the National Center for Renal Health in Peru. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.08.001] [Reference Citation Analysis]
92 Beer L, Inglis S, Malaguti A, Byrne C, Sharkey C, Robinson E, Gillings K, Radley A, Hapca A, Stephens B, Dillon J. Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection. J Viral Hepat 2022;29:646-53. [PMID: 35582875 DOI: 10.1111/jvh.13701] [Reference Citation Analysis]
93 Calleja JL, Aguilera A, Buti M, Crespo J, García F, Jorquera F, Morano LE, Macias J, Lazarus JV. Ten steps to eliminating hepatitis C in hospitals. Nat Rev Gastroenterol Hepatol 2022;19:481-3. [PMID: 35739353 DOI: 10.1038/s41575-022-00647-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Hayes CN, Imamura M, Tanaka J, Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int 2022;42:1935-44. [PMID: 34967486 DOI: 10.1111/liv.15150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
95 Wong YJ, Kumar R, Kumar R, Tan J, Liu CH, Hui VK, Tan SS, Kao JH, Wong GH, Thurairajah PH. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry. J Gastroenterol Hepatol 2022;37:1642-4. [PMID: 35723645 DOI: 10.1111/jgh.15918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
96 Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Matthews GV, Dore GJ; REACH-C Study Group. Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort. J Viral Hepat 2022;29:661-76. [PMID: 35583922 DOI: 10.1111/jvh.13705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Zhang H, Liu Q, Hu S, Zhong M, Peng F, Guo Y, Fang C, Nie M, Tan L, Dai H, Xie X, Peng L, Lan G, Petrakis I. Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/3758744] [Reference Citation Analysis]
98 Shah R, Barclay ST, Peters ES, Fox R, Gunson R, Bradley-Stewart A, Shepherd SJ, MacLean A, Tong L, van Vliet VJE, Ngan Chiu Bong M, Filipe A, Thomson EC, Davis C. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment. Viruses 2022;14:1678. [PMID: 36016300 DOI: 10.3390/v14081678] [Reference Citation Analysis]
99 Patauner F, Stanzione M, Stornaiuolo G, Martone V, Palladino R, Coppola N, Durante-mangoni E, Zampino R. Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series. Pathogens 2022;11:860. [DOI: 10.3390/pathogens11080860] [Reference Citation Analysis]
100 Merola E, Menotti E, Branz G, Michielan A, Seligmann S, Ratti A, Agugiaro F, Moser L, Vettori G, Franceschini A, Mantovani W, Pertile R, de Pretis G, Pravadelli C. Hepatitis C virus burden: Treating and educating people without prejudice. World J Hepatol 2022; 14(7): 1495-1503 [DOI: 10.4254/wjh.v14.i7.1495] [Reference Citation Analysis]
101 Liu CH, Kao JH. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Hepatol Int 2022. [PMID: 35876967 DOI: 10.1007/s12072-022-10390-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Radmanić L, Bodulić K, Šimičić P, Vince A, Lepej SŽ. The Effect of Treatment-Induced Viral Eradication on Cytokine and Growth Factor Expression in Chronic Hepatitis C. Viruses 2022;14:1613. [PMID: 35893679 DOI: 10.3390/v14081613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Brakenhoff SM, de Man RA, de Knegt RJ, Bindels PJE, de Schepper EIT. Epidemiology and management of hepatitis B and C in primary care in the Netherlands: data from the Rijnmond Primary Care database. Family Practice 2022. [DOI: 10.1093/fampra/cmac070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Conway A, Valerio H, Alavi M, Silk D, Treloar C, Hajarizadeh B, Marshall AD, Martinello M, Milat A, Dunlop A, Murray C, Prain B, Henderson C, Amin J, Read P, Marks P, Degenhardt L, Hayllar J, Reid D, Gorton C, Lam T, Christmass M, Wade A, Montebello M, Dore GJ, Grebely J; ETHOS Engage Study Group. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses 2022;14:1555. [PMID: 35891535 DOI: 10.3390/v14071555] [Reference Citation Analysis]
105 Honegger JR, Gowda C. Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children. Curr Opin Infect Dis 2022. [PMID: 35852787 DOI: 10.1097/QCO.0000000000000856] [Reference Citation Analysis]
106 Cornberg M, Stoehr A, Naumann U, Teuber G, Klinker H, Lutz T, Möller H, Hidde D, Lohmann K, Simon K. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R). Viruses 2022;14:1541. [DOI: 10.3390/v14071541] [Reference Citation Analysis]
107 Cepeda JA, Thomas DL, Astemborski J, Rudolph JE, Gicquelais R, Kirk GD, Mehta SH. Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs : A Longitudinal, Community-Based Cohort Study. Ann Intern Med 2022. [PMID: 35816712 DOI: 10.7326/M21-3846] [Reference Citation Analysis]
108 Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. Eur J Med Chem 2022;240:114595. [PMID: 35868125 DOI: 10.1016/j.ejmech.2022.114595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Reddy DVU, Vignesh V. Commonly used Drugs with their Doses in Pediatric Hepatology. Annals of Pediatric Gastroenterology & Hepatology 2022;4:18-19. [DOI: 10.5005/jp-journals-11009-0096] [Reference Citation Analysis]
110 Jain A, Mumtaz K. Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. Avicenna J Med. [DOI: 10.1055/s-0042-1750716] [Reference Citation Analysis]
111 Ferraz MLG, Piccoli LDZ, Rezende R, Borba LA, Junior AP, Cheinquer H, Silva GF, Ferreira PRA, Villela-nogueira CA, Mazo DF, Souza FF, Codes L, Ivantes CAP, Gomide GPM, Pereira GHS, Pessôa MG, França AVC, Pinto ADS, Teixeira R, Bittencourt PL. National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents. The Brazilian Journal of Infectious Diseases 2022;26:102388. [DOI: 10.1016/j.bjid.2022.102388] [Reference Citation Analysis]
112 Nebbia G, Ruf M, Hunter L, Balasegaram S, Wong T, Kulasegaram R, Surey J, Khan Z, Williams J, Karo B, Snell L, Flower B, Evans H, Douthwaite S. VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department. J Viral Hepat 2022;29:559-68. [PMID: 35357750 DOI: 10.1111/jvh.13676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Wong YJ, Nguyen MH. Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs? J Hepatol 2022;77:257-8. [PMID: 35074472 DOI: 10.1016/j.jhep.2021.12.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 D'Ambrosio R, Lampertico P. Is it time to refine HCC surveillance strategies in HCV cured patients? Hepatology 2022;76:9-11. [PMID: 35218241 DOI: 10.1002/hep.32430] [Reference Citation Analysis]
115 Lee J, Ahn SB, Yim SY, An J, Jun DW, Ko MJ, Park DA, Yoo JJ. Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis. J Viral Hepat 2022;29:496-517. [PMID: 35357774 DOI: 10.1111/jvh.13679] [Reference Citation Analysis]
116 Rosati S, Wong A, Marco VD, Pérez-hernandez P, Macedo G, Brixko C, Ranieri R, Campanale F, Basciá A, Fernández-rodríguez C, Lédinghen VD, Maida I, Teti E, Mangia A, Vanstraelen K, Hernández C, Mertens M, Ntalla I, Ramroth H, Jiménez E. Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings. Future Virology 2022;17:419-28. [DOI: 10.2217/fvl-2022-0016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
119 Dietz C, Maasoumy B. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice. Viruses 2022;14:1325. [PMID: 35746796 DOI: 10.3390/v14061325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Badami E, Busà R, Douradinha B, Russelli G, Miceli V, Gallo A, Zito G, Conaldi PG, Iannolo G. Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches. World J Gastroenterol 2022; 28(22): 2417-2428 [DOI: 10.3748/wjg.v28.i22.2417] [Reference Citation Analysis]
121 Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy. JGH Open. [DOI: 10.1002/jgh3.12778] [Reference Citation Analysis]
122 Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022;12:e058757. [PMID: 35676019 DOI: 10.1136/bmjopen-2021-058757] [Reference Citation Analysis]
123 Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matsuo Y, Takatani M, Iijima H, Tanaka J. Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. JGH Open. [DOI: 10.1002/jgh3.12774] [Reference Citation Analysis]
124 Guggisberg H, Nicca D, Kohler A, Bruggmann P, Patrizia Künzler-Heule P. "Shaping the new freedom": A reflexive thematic analysis on patients' post cure needs after years of living with hepatitis C. Swiss Med Wkly 2022;152:w30177. [PMID: 35704926 DOI: 10.4414/smw.2022.w30177] [Reference Citation Analysis]
125 Wildner NH, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze zur Wiesch J. Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition. Front Immunol 2022;13:886646. [DOI: 10.3389/fimmu.2022.886646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun 2022. [PMID: 35666055 DOI: 10.1002/hep4.2015] [Reference Citation Analysis]
127 Barreto SG, Strasser SI, Mccaughan GW, Fink MA, Jones R, Mccall J, Munn S, Macdonald GA, Hodgkinson P, Jeffrey GP, Jaques B, Crawford M, Brooke-smith ME, Chen JW. Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. Cancers 2022;14:2777. [DOI: 10.3390/cancers14112777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Gupta N, Manirambona L, Shumbusho F, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Camus G, Grant PM, Kateera F. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:542-51. [DOI: 10.1016/s2468-1253(21)00399-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
129 Kateera F, Shumbusho F, Manirambona L, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Kabakambira JD, Sylvain H, Camus G, Grant PM, Gupta N. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:533-41. [DOI: 10.1016/s2468-1253(21)00398-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
130 Gutiérrez-rojas L, de la Gándara Martín JJ, García Buey L, Uriz Otano JI, Mena Á, Roncero C. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
132 Opio CK. Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022;7:498-9. [DOI: 10.1016/s2468-1253(21)00465-9] [Reference Citation Analysis]
133 Hosseini-hooshyar S, Hajarizadeh B, Bajis S, Law M, Janjua NZ, Fierer DS, Chromy D, Rockstroh JK, Martin TCS, Ingiliz P, Hung C, Dore GJ, Martinello M, Matthews GV. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. The Lancet HIV 2022;9:e414-27. [DOI: 10.1016/s2352-3018(22)00077-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Zahid H, Aslam K, Dahl EH, Abbassi W, Adan S, Van den Bergh R, Balinska MA, Luck NH. DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series. Oxf Med Case Reports 2022;2022:omac049. [PMID: 35619685 DOI: 10.1093/omcr/omac049] [Reference Citation Analysis]
135 Rossotti R, Merli M, Mazzarelli C, De Carlis RM, Travi G, Vecchi M, Viganò R, Lauterio A, Raimondi A, Belli LS, De Carlis LG, Puoti M. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation. Dig Liver Dis 2022:S1590-8658(22)00500-X. [PMID: 35644890 DOI: 10.1016/j.dld.2022.05.001] [Reference Citation Analysis]
136 Nevola R, Rosato V, Conturso V, Perillo P, Le Pera T, Del Vecchio F, Mastrocinque D, Pappalardo A, Imbriani S, Delle Femine A, Piacevole A, Claar E. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology 2022;11:805. [DOI: 10.3390/biology11060805] [Reference Citation Analysis]
137 Rosato V, Nevola R, Conturso V, Perillo P, Mastrocinque D, Pappalardo A, Le Pera T, Del Vecchio F, Claar E. Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. Biology 2022;11:800. [DOI: 10.3390/biology11060800] [Reference Citation Analysis]
138 Mushtaq S, Hashmi AH, Khan A, Asad Raza Kazmi SM, Manzoor S. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals. Front Pharmacol 2022;13:894460. [PMID: 35571102 DOI: 10.3389/fphar.2022.894460] [Reference Citation Analysis]
139 Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, Carmiel M, Chodick G, Conway B, Song Y, Gasbarrini A, Hüppe D, Plaza FJ, Lampertico P, Alonso MLM, Myles L, Persico M, Ramji A, Sarrazin C, Villa E, Weil C, Otano JIU; CREST Study Group. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. Adv Ther 2022. [PMID: 35543964 DOI: 10.1007/s12325-022-02158-6] [Reference Citation Analysis]
140 Wong YJ, Nguyen MH. Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors-based direct-acting antivirals? Liver Int 2022;42:1207-8. [PMID: 35220647 DOI: 10.1111/liv.15214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Turnes J, Rincón D, Calleja JL, Delgado MB, Rosales JM, Andrade RJ, Manzano ML, Salmerón FJ, López MA, Calvo M, Gómez J, Molina E, Frias YN, Gálvez-fernández RM, Vallejo-senra N, París S, Santos de Lamadrid R, Olveira A. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. Gastroenterología y Hepatología (English Edition) 2022;45:342-349. [DOI: 10.1016/j.gastre.2021.05.007] [Reference Citation Analysis]
142 Gabbia D, Roverso M, Sarcognato S, Zanotto I, Ferri N, Russo FP, Guido M, Bogialli S, De Martin S. The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology 2022;11:693. [DOI: 10.3390/biology11050693] [Reference Citation Analysis]
143 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Rusie D, Mercan Stanciu A, Toma L, Iliescu EL. Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals. Cureus 2022. [DOI: 10.7759/cureus.24506] [Reference Citation Analysis]
145 Saranskaya Y, Kiseleva L, Il'mukhina L. OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT. Ulyanovsk Medico-biological Journal 2022. [DOI: 10.34014/2227-1848-2022-1-39-48] [Reference Citation Analysis]
146 Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Front Immunol 2022;13:882064. [DOI: 10.3389/fimmu.2022.882064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Ades AE, Gordon F, Scott K, Collins IJ, Thorne C, Pembrey L, Chappell E, Mariné-Barjoan E, Butler K, Indolfi G, Gibb DM, Judd A. Spontaneous Clearance Of Vertically Acquired Hepatitis C Infection: Implications For Testing And Treatment. Clin Infect Dis 2022:ciac255. [PMID: 35396848 DOI: 10.1093/cid/ciac255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
149 Babigumira JB, Karichu JK, Clark S, Cheng MM, Garrison LP, Maniecki MB, Hamid SS. Assessing the potential cost-effectiveness of centralized vs point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison.. [DOI: 10.1101/2022.03.31.22273228] [Reference Citation Analysis]
150 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterología y Hepatología (English Edition) 2022;45:265-273. [DOI: 10.1016/j.gastre.2021.09.006] [Reference Citation Analysis]
151 Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2022;76:874-82. [PMID: 34856322 DOI: 10.1016/j.jhep.2021.11.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
152 Aoki Y, Kinoshita A, Osawa A, Kano T, Sato Y, Mitsuyoshi Y, Koike K, Saruta M. A case of an elderly patient with chronic hepatitis C exacerbated by chemotherapy for malignant lymphoma and improved by direct-acting antivirals therapy. Acta hepatologica Japonica 2022;63:196-202. [DOI: 10.2957/kanzo.63.196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Schwarz T, Horváth I, Fenz L, Schmutterer I, Rosian-schikuta I, Mårdh O. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation. International Journal of Drug Policy 2022;102:103588. [DOI: 10.1016/j.drugpo.2022.103588] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Hernández-Conde M, Calleja JL. Editorial: clinical impact of sofosbuvir renal toxicity-more light on the way. Aliment Pharmacol Ther 2022;55:1052-3. [PMID: 35362131 DOI: 10.1111/apt.16861] [Reference Citation Analysis]
155 Diepolder H. Hepatitis A bis E. CME 2022;19:53-65. [DOI: 10.1007/s11298-022-2344-8] [Reference Citation Analysis]
156 Krekulova L, Oktabec Z, Riley LW. Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection. Int J Environ Res Public Health 2022;19:4158. [PMID: 35409839 DOI: 10.3390/ijerph19074158] [Reference Citation Analysis]
157 Dammacco F, Lauletta G, Vacca A. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med. [DOI: 10.1007/s10238-022-00808-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice . World J Gastroenterol 2022; 28(12): 1226-1238 [DOI: 10.3748/wjg.v28.i12.1226] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Yen H, Chen Y, Lai J, Chen H, Yao C, Huang S, Liu I, Zeng Y, Yang F, Siao F, Chen M, Su P. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. JCM 2022;11:1853. [DOI: 10.3390/jcm11071853] [Reference Citation Analysis]
160 Burkard T, Proske N, Resner K, Collignon L, Knegendorf L, Friesland M, Verhoye L, Sayed IM, Brüggemann Y, Nocke MK, Behrendt P, Wedemeyer H, Meuleman P, Todt D, Steinmann E. Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. Cells 2022;11:927. [PMID: 35326378 DOI: 10.3390/cells11060927] [Reference Citation Analysis]
161 Colombatto P, Palmisano E, Ricco G, Cavallone D, Oliveri F, Coco B, Salvati A, Romagnoli V, Surace L, Vatteroni M, Pistello M, Virdis A, Bonino F, Brunetto MR. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. JCM 2022;11:1406. [DOI: 10.3390/jcm11051406] [Reference Citation Analysis]
162 Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J. Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences. Int J Mol Sci 2022;23:2787. [PMID: 35269929 DOI: 10.3390/ijms23052787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, Hayes PC, Gunson RN, Templeton K, Goldberg DJ, Hickman M, Hutchinson SJ. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol 2022;76:549-57. [PMID: 34634387 DOI: 10.1016/j.jhep.2021.09.038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
164 Harney BL, Whitton B, Paige E, Brereton R, Weiss R, Membrey D, Wade AJ, Iser D, Kemp W, Roberts SK, Spelman T, Sacks-Davis R, Hellard ME, Doyle JS. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Liver Int 2022;42:522-31. [PMID: 34821021 DOI: 10.1111/liv.15107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Ongaro M, Negro F. Hépatite B et C: une mise à jour sur lʼhépatite virale chronique. Schweiz Gastroenterol 2022;3:19-27. [DOI: 10.1007/s43472-022-00062-6] [Reference Citation Analysis]
166 Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, Hickman M, Hutchinson S, Dillon JF. Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther 2022;55:568-79. [PMID: 34877667 DOI: 10.1111/apt.16728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
167 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Enomoto M, Vutien P, Kawada N. Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance? Hepatol Commun 2022;6:445-7. [PMID: 35202513 DOI: 10.1002/hep4.1864] [Reference Citation Analysis]
169 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Lazarus JV, Villota-rivas M, Fernández I, Gea F, Ryan P, López SA, Guy D, Calleja JL, García-samaniego J. A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Commun Med 2022;2. [DOI: 10.1038/s43856-022-00077-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Brown RS Jr, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, Ferreira R, Feld JJ. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther 2022. [PMID: 35174470 DOI: 10.1007/s40121-022-00599-8] [Reference Citation Analysis]
172 Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Chen Y, Chang T, Chen C, Cheng P, Lo C, Mo L, Chen C, Huang C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Huang J, Yang C, Hu J, Lin C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Dai C, Kao J, Chuang W, Lin H, Chen C, Tseng K, Yu M; on behalf of TACR investigators. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses 2022;14:333. [DOI: 10.3390/v14020333] [Reference Citation Analysis]
174 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
175 Howe AY, Rodrigo C, Cunningham E, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, di Maio VC, Chulanov V, Pawlotsky J, Harrigan PR, Ceccherini-silberstein F, Garcia F, Martinello M, Matthews G, Fernando FF, Esteban JI, Müllhaupt B, Wiesch JSZ, Buggisch P, Neumann-haefelin C, Berg T, Berg CP, Schattenberg JM, Moreno C, Stauber R, Lloyd A, Dore G, Applegate T, Ignacio J, Garcia-cehic D, Gregori J, Rodriguez-frias F, Rando A, Angelico M, Andreoni M, Babudieri S, Bertoli A, Cento V, Coppola N, Craxì A, Paolucci S, Parruti G, Pasquazzi C, Perno CF, Teti E, Vironet C, Lannergård A, Duberg A, Aleman S, Gutteberg T, Soulier A, Gourgeon A, Chevaliez S, Pol S, Carrat F, Salmon D, Kaiser R, Knopes E, Gomes P, de Kneght R, Rijnders B, Poljak M, Lunar M, Usubillaga R, Seguin C, Tay E, Wilson C, Wang DS, George J, Kok J, Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez O, García-herola A, Montero J, Freyre C, Grau C, Cabezas J, Jimenez M, Rodriguez MAM, Quilez C, Pardo MR, Muñoz-medina L, Figueruela B. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100462] [Reference Citation Analysis]
176 Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antivir Ther 2022;27:13596535211072672. [PMID: 35491553 DOI: 10.1177/13596535211072672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Chen C, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Chang TS, Huang J, Yang C, Hu J, Lin C, Chen C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Mo L, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Liu C, Dai C, Chuang W, Lin H, Kao J, Yu M. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.012] [Reference Citation Analysis]
178 Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther 2022;55:422-33. [PMID: 34812502 DOI: 10.1111/apt.16691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
179 D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022;76:302-10. [PMID: 34592366 DOI: 10.1016/j.jhep.2021.09.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
180 Yato K, Matsuda M, Watanabe N, Watashi K, Aizaki H, Kato T, Tamura K, Wakita T, Muramatsu M, Suzuki R. Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208 [DOI: 10.4254/wjh.v14.i1.195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
183 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Tada T, Kurosaki M, Tamaki N, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Nakamura S, Izumi N. A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. JGH Open 2022;6:20-8. [PMID: 35071784 DOI: 10.1002/jgh3.12690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
186 Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274 [DOI: 10.3748/wjg.v28.i2.263] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Hsieh M, Kao T, Hsieh T, Kao C, Peng C, Lai H, Chuang P, Kao J. Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232110676. [DOI: 10.1177/20406223211067631] [Reference Citation Analysis]
188 Liberto MC, Marascio N. Special Issue "Chronic HCV Infection: Clinical Advances and Eradication Perspectives". J Clin Med 2022;11:359. [PMID: 35054053 DOI: 10.3390/jcm11020359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
190 Pabjan P, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? Viruses 2022;14:96. [PMID: 35062302 DOI: 10.3390/v14010096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
191 Flores GL, Mota JC, da Silva Andrade LT, Lopes RS, Bastos FI, Villar LM, Komatsu H. Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/7348755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
192 Macpherson I, Brennan PN, Dillon JF. Hepatitis B, Hepatitis C and Liver Disease: A Review for the Dental Practitioner. Dent Update 2022;49:26-30. [DOI: 10.12968/denu.2022.49.1.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Tunney R, Prince M, Athwal V. Chronic Hepatitis C. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_9] [Reference Citation Analysis]
194 Zhao Y, He X, Ji F. Antiviral Therapy for Hepatitis C Virus Infection in Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_2] [Reference Citation Analysis]
195 Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 2022;76:174-85. [PMID: 34600000 DOI: 10.1016/j.jhep.2021.09.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
196 Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022;71:176-84. [PMID: 33408122 DOI: 10.1136/gutjnl-2020-323569] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
197 Romero S, Holmes JA. Editorial: hepatocellular carcinoma risk prediction models following DAA-mediated SVR-more evidence needed. Aliment Pharmacol Ther 2022;55:135-6. [PMID: 34907553 DOI: 10.1111/apt.16695] [Reference Citation Analysis]
198 Von den Hoff DW, Berden FAC, Drenth JPH, Schellekens AFA; HepNed, NISPA. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project. Addict Sci Clin Pract 2022;17:67. [PMID: 36451175 DOI: 10.1186/s13722-022-00350-1] [Reference Citation Analysis]
199 Lee WJ, Foster GR. Hepatitis C. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00268-6] [Reference Citation Analysis]
200 O’connell KA, Mari A, Van Voorhees AS. Laboratory Monitoring: HIV, TB and Hepatitis. Updates in Clinical Dermatology 2022. [DOI: 10.1007/978-3-030-92938-1_2] [Reference Citation Analysis]
201 Marcellusi A, Mennini FS, Ruf M, Galli C, Aghemo A, Brunetto MR, Babudieri S, Craxi A, Andreoni M, Kondili LA. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. Liver Int 2022;42:26-37. [PMID: 34582627 DOI: 10.1111/liv.15070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
202 Shalimar, Priya S, Gupta H, Bansal B, Elhence A, Krishna Kishore RV, Goel A. A Systematic Review of Risk Factors for Hepatitis C Virus Infection Among Low-Risk Population in India. J Clin Exp Hepatol 2022;12:1438-44. [PMID: 36340297 DOI: 10.1016/j.jceh.2022.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Kermani FR, Hosseini KM, Kafi-abad SA, Maghsudlu M, Sharifi Z, Mansournia MA. Quantification of hepatitis C virus in viremic blood donors in Iran: Need to reinforce post-donation follow up. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103353] [Reference Citation Analysis]
204 Bamdad T, Yari A. Hepatitis Viruses. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00078-1] [Reference Citation Analysis]
205 Reiser M. Akute und chronische Virushepatitis – Begutachtung. Die Ärztliche Begutachtung 2022. [DOI: 10.1007/978-3-662-61937-7_114-1] [Reference Citation Analysis]
206 Chan G, Lynch B, Murray MA, Hannan MM. Opportunistic Bacterial, Fungal and Viral Infections in Lung Transplantation. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00259-6] [Reference Citation Analysis]
207 Ampuero J, Carmona I, Sousa F, Rosales JM, López-Garrido Á, Casado M, Figueruela B, Aparicio-Serrano A, Andrade R, Guerra-Veloz MF, Maraver M, Pascasio JM, Estévez M, Romero-Gomez M. A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. Am J Gastroenterol 2022;117:138-46. [PMID: 34817975 DOI: 10.14309/ajg.0000000000001503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
208 Dietz CA, Wedemeyer H. Rolle der Hepatitis-B-Impfung in der Prävention des hepatozellulären Karzinoms. Onkologe 2022;28:15-22. [DOI: 10.1007/s00761-021-01036-0] [Reference Citation Analysis]
209 Solomon SS, Wagner-cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00397-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
210 Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol 2022;19:533-50. [PMID: 35595834 DOI: 10.1038/s41575-022-00608-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
211 Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC, Kao JH, Chuang WL, Yu ML; TACR investigators. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infect Dis Ther 2021. [PMID: 34967920 DOI: 10.1007/s40121-021-00576-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Pol S, Fouad F, Lemaitre M, Rodriguez I, Lada O, Rabiega P, Benabadji E, Roudot-Thoraval F. Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). Lancet Reg Health Eur 2022;13:100281. [PMID: 34950924 DOI: 10.1016/j.lanepe.2021.100281] [Reference Citation Analysis]
213 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
214 Varotti G, Dodi F, Paoletti E, Bruno A, Fontana I. Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient. Case Rep Transplant 2021;2021:1948560. [PMID: 34931152 DOI: 10.1155/2021/1948560] [Reference Citation Analysis]
215 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
216 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
217 Husa P, Husa P. Acute searching and early diagnosis of HCV infected persons. Vnitr Lek 2021;67:455-458. [DOI: 10.36290/vnl.2021.119] [Reference Citation Analysis]
218 Djebali-Trabelsi A, Marot A, André C, Deltenre P. Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study. J Viral Hepat 2021;28:1756-8. [PMID: 34342098 DOI: 10.1111/jvh.13588] [Reference Citation Analysis]
219 Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, Belmonte E, Ferrusquía-Acosta J, Magaz M, Perez-Campuzano V, Olivas P, Bauer D, Casanovas G, Torres F, Mariño Z, Forns X, Hernández-Gea V, García-Pagán JC. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 2021;41:2954-64. [PMID: 34242479 DOI: 10.1111/liv.15009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
220 Alem SA, Eletreby R, Abdellatif Z, Ramadan A, Nagy A, AbdAllah M, Elsharkawy A, Fouad R, Esmat G, Tantawi O. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. Eur J Gastroenterol Hepatol 2021;33:e746-52. [PMID: 34231522 DOI: 10.1097/MEG.0000000000002240] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Massari M, Coppola C, Biliotti E, Giorgini A, Laccabue D, Ciancio A, Blanc PL, Margotti M, Ieluzzi D, Brunetto MR, Barbaro F, Russo FP, Beretta I, Morsica G, Verucchi G, Saracino A, Galli M, Kondili LA; PITER Collaborating Group. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig Liver Dis 2021;53:1603-9. [PMID: 33893040 DOI: 10.1016/j.dld.2021.03.020] [Reference Citation Analysis]
222 Huang JF, Hsieh MY, Wei YJ, Hung JY, Huang HT, Huang CI, Yeh ML, Huang CF, Jang TY, Hsu PY, Liang PC, Dai CY, Lin ZY, Yu ML, Chuang WL. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). Hepatol Int 2021. [PMID: 34850326 DOI: 10.1007/s12072-021-10275-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Yamana Y, Kanda T, Matsumoto N, Honda M, Kumagawa M, Sasaki R, Kanezawa S, Mizutani T, Yamagami H, Masuzaki R, Ishii T, Nirei K, Moriyama M. Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. J Clin Med 2021;10:5529. [PMID: 34884231 DOI: 10.3390/jcm10235529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Petroff D, Bätz O, Jedrysiak K, Kramer J, Berg T, Wiegand J. The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings. Viruses 2021;13:2327. [PMID: 34835133 DOI: 10.3390/v13112327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
227 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
228 Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver Int 2021;41:2601-10. [PMID: 34154034 DOI: 10.1111/liv.14991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
229 Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021;28:1635-42. [PMID: 34448313 DOI: 10.1111/jvh.13600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. Glob Health Med 2021;3:276-82. [PMID: 34782869 DOI: 10.35772/ghm.2021.01075] [Reference Citation Analysis]
231 Mikulska M, Knelange N, Nicolini LA, Tridello G, Santarone S, Di Bartolomeo P, de la Camara R, Cuéllar C, Velardi A, Perruccio K, Ljungman P, Zaucha J, Piekarska A, Basak G, Karakulska-Prystupiuk E, Angelucci E, Ciceri F, Lupo-Stanghellini MT, Fouillard L, García-Cadenas I, Menconi M, Blau IW, Nassi L, Cesaro S, Styczynski J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. J Infect 2021:S0163-4453(21)00539-9. [PMID: 34757138 DOI: 10.1016/j.jinf.2021.10.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 McCormick CA, Domegan L, Carty PG, Drew R, McAuliffe FM, O'Donohoe O, White N, Garvey P, O'Grady M, De Gascun CF, McCormick PA. Routine screening for hepatitis C in pregnancy is cost-effective in a large urban population in Ireland: a retrospective study. BJOG 2022;129:322-7. [PMID: 34706147 DOI: 10.1111/1471-0528.16984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Granozzi B, Guardigni V, Badia L, Rosselli Del Turco E, Zuppiroli A, Tazza B, Malosso P, Pieralli S, Viale P, Verucchi G. Out-of-Hospital Treatment of Hepatitis C Increases Retention in Care among People Who Inject Drugs and Homeless Persons: An Observational Study. J Clin Med 2021;10:4955. [PMID: 34768474 DOI: 10.3390/jcm10214955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
235 Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Caso Ó, Fernández I. Authors' response to Cai et al. on their commentary on "Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals" (Int J Surg 2021, 106096). Int J Surg 2021;95:106146. [PMID: 34688929 DOI: 10.1016/j.ijsu.2021.106146] [Reference Citation Analysis]
236 Esaulenko EV, Dzemova AA, Trifonova GF, Bushmanova AD, Novak KE, Ogurtsova SV, Butskaya MY. Hepatitis С in Russia and the Northwest federal region of Russia: results of the first stage the global programme of infection elimination. VIČ-infekc immunosupr 2021;13:40-51. [DOI: 10.22328/2077-9828-2021-13-3-40-51] [Reference Citation Analysis]
237 Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J 2021;9:1101-2. [PMID: 34687156 DOI: 10.1002/ueg2.12167] [Reference Citation Analysis]
238 Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. Kaohsiung J Med Sci 2021. [PMID: 34687140 DOI: 10.1002/kjm2.12465] [Reference Citation Analysis]
239 Chemello L, Cavalletto L, Ferrari S, Monaco S. Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C. Minerva Gastroenterol (Torino) 2021;67:234-43. [PMID: 34672486 DOI: 10.23736/S2724-5985.21.02865-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
240 Kim KA, Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Ki M, Choi HY, Paik D, Jeong SH. Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. Epidemiol Health 2021;43:e2021077. [PMID: 34645207 DOI: 10.4178/epih.e2021077] [Reference Citation Analysis]
241 Mastrorosa I, Tempestilli M, Notari S, Lorenzini P, Fabbri G, Grilli E, Bellagamba R, Vergori A, Cicalini S, Ammassari A, Agrati C, Antinori A. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. Eur J Drug Metab Pharmacokinet 2021. [PMID: 34623616 DOI: 10.1007/s13318-021-00725-w] [Reference Citation Analysis]
242 Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group, Protocol Steering Committee, Coordinating Centre, Site Principal Investigators. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol 2021;75:829-39. [PMID: 34023350 DOI: 10.1016/j.jhep.2021.04.056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
243 Marcos-Fosch C, Cabezas J, Crespo J, Buti M. Anti-epileptic drugs and hepatitis C therapy: Real-world experience. J Hepatol 2021;75:984-5. [PMID: 34126106 DOI: 10.1016/j.jhep.2021.05.040] [Reference Citation Analysis]
244 Ding YJ, Lu CK, Chen WM, Tung SY, Wei KL, Shen CH, Hsieh YY, Yen CW, Chang KC, Chiu WN, Hung CH, Lu SN, Chang TS. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis. J Gastroenterol Hepatol 2021;36:2911-6. [PMID: 33978973 DOI: 10.1111/jgh.15546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
245 Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021;28:1474-83. [PMID: 34339561 DOI: 10.1111/jvh.13586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ades AE, Gordon F, Scott K, Collins J, Thorne C, Pembrey L, Chappell E, Mariné-barjoan E, Butler K, Indolfi G, Gibb DM, Judd A. Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment.. [DOI: 10.1101/2021.09.29.21264077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Ades AE, Gordon F, Scott K, Collins J, Thorne C, Pembrey L, Chappell E, Mariné-barjoan E, Butler K, Indolfi G, Gibb DM, Judd A. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission.. [DOI: 10.1101/2021.09.28.21264075] [Reference Citation Analysis]
248 Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Lin JJ, Loucks CM, Trueman JN, Drögemöller BI, Wright GEB, Yoshida EM, Ford JA, Lee SS, Kim RB, Al-Judaibi B, Schwarz UI, Ramji A, Tam E, Ross CJ, Carleton BC. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Biomed Pharmacother 2021;143:112195. [PMID: 34562771 DOI: 10.1016/j.biopha.2021.112195] [Reference Citation Analysis]
251 Boumbaly S, Serikova EN, Semenov AV, Ostankova YV, Valutite DE, Schemelev AN, Zueva EB, Balde TA, Baimova RR, Totolian AA. Significance of parenteral viral hepatitis laboratory diagnostics in the Republic of Guinea. Zhurnal mikrobiologii, èpidemiologii i immunobiologii 2021;98:440-449. [DOI: 10.36233/0372-9311-116] [Reference Citation Analysis]
252 Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
254 Ružić M, Rajić N, Fabri M, Urošević I, Jojkić MD, Preveden T, Pete M, Rajić N. Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible? Mediterr J Hematol Infect Dis 2021;13:e2021058. [PMID: 34527210 DOI: 10.4084/MJHID.2021.058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
255 Yilmaz B, Ruckstuhl L, Müllhaupt B, Magenta L, Kuster MH, Clerc O, Torgler R, Semmo N. Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. Pharmaceuticals (Basel) 2021;14:931. [PMID: 34577631 DOI: 10.3390/ph14090931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 D'Ambrosio R, Ioannou GN. Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatol Commun 2021;5:1465-8. [PMID: 34510832 DOI: 10.1002/hep4.1733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Jia Y, Yue W, Gao Q, Tao R, Zhang Y, Fu X, Liu Y, Liu L, Feng Y, Xia X. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiol Spectr 2021;9:e0029721. [PMID: 34479413 DOI: 10.1128/Spectrum.00297-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Zeng DY, Li JM, Lin S, Dong X, You J, Xing QQ, Ren YD, Chen WM, Cai YY, Fang K, Hong MZ, Zhu Y, Pan JS. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol 2021;75:547-56. [PMID: 33961940 DOI: 10.1016/j.jhep.2021.04.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
260 Dotters-Katz SK, Kuller JA, Hughes BL; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. Am J Obstet Gynecol 2021;225:B8-B18. [PMID: 34116035 DOI: 10.1016/j.ajog.2021.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
261 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel, Chair:, EASL Governing Board representative:, Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 120.5] [Reference Citation Analysis]
262 McDonald SA, Barclay ST, Innes HA, Fraser A, Hayes PC, Bathgate A, Dillon JF, Went A, Goldberg DJ, Hutchinson SJ. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. J Viral Hepat 2021;28:1246-55. [PMID: 34002914 DOI: 10.1111/jvh.13543] [Reference Citation Analysis]
263 De A, Roy A, Verma N, Mishra S, Premkumar M, Taneja S, Singh V, Duseja A. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton) 2021. [PMID: 34453374 DOI: 10.1111/nep.13968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
264 Chen YC, Li CH, Ko PH, Lee CC, Syu RJ, Tseng CW, Tseng KC. Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. PLoS One 2021;16:e0256505. [PMID: 34437608 DOI: 10.1371/journal.pone.0256505] [Reference Citation Analysis]
265 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
266 Ryan P, Valencia J, Cuevas G, Torres-Macho J, Troya J, Pueyo Á, José Muñoz-Gómez M, Muñoz-Rivas N, Vázquez-Morón S, Martinez I, Lazarus JV, Resino S. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. Int J Drug Policy 2021;96:103424. [PMID: 34429222 DOI: 10.1016/j.drugpo.2021.103424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
267 Rubino C, Trapani S, Indolfi G. Sofosbuvir/velpatasvir for the treatment of Hepatitis C in pediatric patients. Expert Rev Gastroenterol Hepatol 2021. [PMID: 34338120 DOI: 10.1080/17474124.2021.1963231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
268 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
269 Bartres C, Soy G, Forns X. Hepatitis C therapy and anticonvulsants. Gastroenterología y Hepatología (English Edition) 2021;44:536. [DOI: 10.1016/j.gastre.2020.11.004] [Reference Citation Analysis]
270 Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021;28:1206-18. [PMID: 34003549 DOI: 10.1111/jvh.13546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
271 Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021;41:1802-14. [PMID: 33497016 DOI: 10.1111/liv.14797] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
272 Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, Takashima T, Aizawa N, Ikeda N, Enomoto H, Kumada T, Iijima H. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 2021;51:860-9. [PMID: 34046970 DOI: 10.1111/hepr.13677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
273 Iliescu L. Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.96551] [Reference Citation Analysis]
274 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
275 Frosi A. Extrahepatic Manifestations of Hepatitis C Infection. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Mohammed AS, Balapure A, Khan AA, Khaja MN, Ganesan R, Dutta JR. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3. Analyst 2021;146:4767-74. [PMID: 34231566 DOI: 10.1039/d1an00590a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
277 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
278 Garbuzenko DV. Diagnostic and risk stratification aspects of liver fibrosis progression in chronic hepatitis B and C viral infection. Medical Journal of the Russian Federation 2021;27:373-384. [DOI: 10.17816/0869-2106-2021-27-4-373-384] [Reference Citation Analysis]
279 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
280 Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL; STOP-HCV Consortium. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 2021:S1198-743X(21)00373-6. [PMID: 34245902 DOI: 10.1016/j.cmi.2021.06.042] [Reference Citation Analysis]
281 Chevaliez S, Roudot-Thoraval F, Hézode C, Pawlotsky JM, Njouom R. Performance of rapid diagnostic tests for HCV infection in serum or plasma. Future Microbiol 2021;16:713-9. [PMID: 34227402 DOI: 10.2217/fmb-2020-0295] [Reference Citation Analysis]
282 Sasso FC, Pafundi PC, Caturano A, Galiero R, Vetrano E, Nevola R, Petta S, Fracanzani AL, Coppola C, Di Marco V, Solano A, Lombardi R, Giordano M, Craxi A, Perrella A, Sardu C, Marfella R, Salvatore T, Adinolfi LE, Rinaldi L. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2021;31:2345-53. [DOI: 10.1016/j.numecd.2021.04.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
283 Klinker H, Naumann U, Rössle M, Berg T, Bondin M, Lohmann K, Koenig B, Zeuzem S, Cornberg M. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. Liver Int 2021;41:1518-22. [PMID: 33966349 DOI: 10.1111/liv.14937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
284 Martin MT, Patel S, Kulik L, Chan C. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. J Hepatol 2021;75:251-4. [PMID: 33652031 DOI: 10.1016/j.jhep.2021.02.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
285 Chang KC, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, Chen YH, Chen CH, Yen CW, Xu HW, Tung WL, Hung CH, Lu SN, Chang TS. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 2021;11:13543. [PMID: 34188161 DOI: 10.1038/s41598-021-93095-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
286 D'Ambrosio R, Degasperi E, Lampertico P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J Hepatocell Carcinoma 2021;8:713-39. [PMID: 34235108 DOI: 10.2147/JHC.S292139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
287 Jachs M, Binter T, Chromy D, Schalk H, Pichler K, Bauer D, Simbrunner B, Hartl L, Schmidbauer C, Mayer F, Strassl R, Mandorfer M, Gschwantler M, Reiberger T. Outcomes of an HCV elimination program targeting the Viennese MSM population. Wien Klin Wochenschr 2021;133:635-40. [PMID: 34181068 DOI: 10.1007/s00508-021-01898-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
288 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
290 Garrigou O, Ortonne V, Soulier A, Chevaliez S. Dried blood spot sampling for hepatitis C virus infection: A new tool to simplify testing algorithms. J Clin Virol 2021;141:104876. [PMID: 34126544 DOI: 10.1016/j.jcv.2021.104876] [Reference Citation Analysis]
291 Turnes J, Rincón D, Calleja JL, Delgado MB, Rosales JM, Andrade RJ, Manzano ML, Salmerón FJ, López MA, Calvo M, Gómez J, Molina E, Frias YN, Gálvez-Fernández RM, Vallejo-Senra N, París S, Santos de Lamadrid R, Olveira A. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study. Gastroenterol Hepatol 2021:S0210-5705(21)00198-9. [PMID: 34129903 DOI: 10.1016/j.gastrohep.2021.05.015] [Reference Citation Analysis]
292 Ortonne V, Wlassow M, Hézode C, François M, Rosa I, Pawlotsky JM, Chevaliez S. Diagnosis and monitoring of hepatitis C virus infection using the cobas® HCV test for use on the cobas® 4800 system. J Clin Virol 2021;141:104873. [PMID: 34111663 DOI: 10.1016/j.jcv.2021.104873] [Reference Citation Analysis]
293 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
294 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched. World J Gastroenterol 2021; 27(21): 2771-2783 [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
295 Morelli MC, Rendina M, La Manna G, Alessandria C, Pasulo L, Lenci I, Bhoori S, Messa P, Biancone L, Gesualdo L, Russo FP, Petta S, Burra P; Italian Association for the Study of Liver, and the Italian Society of Nephrology. Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). Dig Liver Dis 2021;53 Suppl 2:S49-86. [PMID: 34074490 DOI: 10.1016/j.dld.2021.03.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
296 Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland. Infect Genet Evol 2021;93:104949. [PMID: 34087494 DOI: 10.1016/j.meegid.2021.104949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Ohata PJ, Su Lwin HM, Han WM, Khwairakpam G, Tangkijvanich P, Matthews GV, Avihingsanon A. Elimination of hepatitis C among HIV-positive population in Asia: old and new challenges. Future Virology 2021;16:407-417. [DOI: 10.2217/fvl-2021-0015] [Reference Citation Analysis]
298 Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Adv Ther 2021;38:3409-26. [PMID: 34021887 DOI: 10.1007/s12325-021-01753-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
299 Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265-77. [PMID: 33655714 DOI: 10.1111/liv.14849] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
300 Huiban L, Stanciu C, Muzica CM, Cuciureanu T, Chiriac S, Zenovia S, Burduloi VM, Petrea O, Sîngeap AM, Gîrleanu I, Sfarti C, Cojocariu C, Trifan A. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. Healthcare (Basel) 2021;9:651. [PMID: 34072635 DOI: 10.3390/healthcare9060651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Cohen-Bucay A, Francis JM, Gordon CE. Progress in hepatitis C virus management in chronic kidney disease. Curr Opin Nephrol Hypertens 2021;30:493-500. [PMID: 34054074 DOI: 10.1097/MNH.0000000000000729] [Reference Citation Analysis]
302 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
303 Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One 2021;16:e0251934. [PMID: 34014993 DOI: 10.1371/journal.pone.0251934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
304 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
305 Deng H, Guo F, Yu W, Li L, Xia Y, Guan Y, Li J. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients. Virus Res 2021;302:198453. [PMID: 33991622 DOI: 10.1016/j.virusres.2021.198453] [Reference Citation Analysis]
306 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
307 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
308 Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, Vestito A, Festi D, Colecchia A. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151-63. [PMID: 34027932 DOI: 10.23736/S2724-5985.20.02793-2] [Reference Citation Analysis]
309 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
310 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
311 Husa P, Snopkova S, Zavrelova J, Zlamal F, Svacinka R, Husa P. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021;165:146-51. [PMID: 33928944 DOI: 10.5507/bp.2021.023] [Reference Citation Analysis]
312 Alkhatib M, Di Maio VC, De Murtas V, Polilli E, Milana M, Teti E, Fiorentino G, Calvaruso V, Barbaliscia S, Bertoli A, Scutari R, Carioti L, Cento V, Santoro MM, Orro A, Maida I, Lenci I, Sarmati L, Craxì A, Pasquazzi C, Parruti G, Babudieri S, Milanesi L, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, Svicher V, Salpini R, On Behalf Of Hirma Hepatocarcinoma Innovative Research MArkers And Fondazione Vironet C Hcv Virology Italian Resistance. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b. Viruses 2021;13:743. [PMID: 33922732 DOI: 10.3390/v13050743] [Reference Citation Analysis]
313 Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide F, Matera G, Torti C, Liberto MC, Ciccaglione AR. Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. J Clin Med 2021;10:1655. [PMID: 33924449 DOI: 10.3390/jcm10081655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Morales-Arraez D, Hernández-Bustabad A, Medina-Alonso MJ, Santiago-Gutiérrez LG, García-Gil S, Diaz-Flores F, Pérez-Pérez V, Nazco J, Fernandez de Rota Martin P, Gutiérrez F, Hernández-Guerra M. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy 2021;94:103235. [PMID: 33838399 DOI: 10.1016/j.drugpo.2021.103235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
315 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
316 Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. J Pers Med 2021;11:281. [PMID: 33917196 DOI: 10.3390/jpm11040281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 García-Crespo C, Gallego I, Soria ME, de Ávila AI, Martínez-González B, Vázquez-Sirvent L, Lobo-Vega R, Moreno E, Gómez J, Briones C, Gregori J, Quer J, Domingo E, Perales C. Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus. Viruses 2021;13:616. [PMID: 33916702 DOI: 10.3390/v13040616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
318 Kaps L, Ahlbrand CJ, Gadban R, Nagel M, Labenz C, Klimpke P, Holtz S, Boedecker S, Michel M, Kremer WM, Hilscher M, Galle PR, Kraus D, Schattenberg JM, Weinmann-Menke J. Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS One 2021;16:e0249342. [PMID: 33793644 DOI: 10.1371/journal.pone.0249342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
319 Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators, Spanish GEHEP-004 Collaborators, Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol 2021;74:801-10. [PMID: 33220331 DOI: 10.1016/j.jhep.2020.11.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
320 Solitano V, Aghemo A. Sofosbuvir in HCV patients with chronic kidney disease: No time for caution. Liver Int 2021;41:646-8. [PMID: 33730762 DOI: 10.1111/liv.14845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Shumbusho F, Liu AF, Kateera F, Kabahizi J, Nsanzaimana S, Serumondo J, Damascene Makuza J, Grant PM, Musabeyezu E, Muvunyi C, Gupta N. Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan Africa. J Viral Hepat 2021;28:682-6. [PMID: 33421247 DOI: 10.1111/jvh.13467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
323 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
324 Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, McStraw N, Fathy M, Fawzy MA, Zaki MYW, Daly AK, Maurício JP, Burt AD, Haugk B, Cordell HJ, Bianco C, Dufour JF, Valenti L, Anstee QM, Reeves HL. A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? Cancers (Basel) 2021;13:1412. [PMID: 33808740 DOI: 10.3390/cancers13061412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
325 Sohn W. Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma. Korean J Intern Med 2021;36:286-7. [PMID: 33725434 DOI: 10.3904/kjim.2021.078] [Reference Citation Analysis]
326 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Carrasco T, Barquín D, Ndarabu A, Fernández-Alonso M, Rubio-Garrido M, Carlos S, Makonda B, Holguín Á, Reina G. HCV Diagnosis and Sequencing Using Dried Blood Spots from Patients in Kinshasa (DRC): A Tool to Achieve WHO 2030 Targets. Diagnostics (Basel) 2021;11:522. [PMID: 33804260 DOI: 10.3390/diagnostics11030522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
328 Besombes J, Pronier C, Lefevre C, Lagathu G, Maillard A, Grolhier C, Thibault V. Performances of NeuMoDx™, a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. Clin Microbiol Infect 2021;27:1693.e9-1693.e15. [PMID: 33677082 DOI: 10.1016/j.cmi.2021.02.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
330 Mangia A, Albanese AP, Bourliére M, Craxi A, Dieterich D, Solomon S, Vanstraelen K, Hernandez C, Turnes J. Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways. Adv Ther 2021;38:1397-403. [PMID: 33590446 DOI: 10.1007/s12325-021-01636-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Aranday-Cortes E, McClure CP, Davis C, Irving WL, Adeboyejo K, Tong L, da Silva Filipe A, Sreenu V, Agarwal K, Mutimer D, Stone B, Cramp ME, Thomson EC, Ball JK, McLauchlan J. Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa. J Infect Dis 2021:jiab110. [PMID: 33668068 DOI: 10.1093/infdis/jiab110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
333 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
334 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Hagymási K. The Nobel Prize in Physiology or Medicine-2020. Struct Chem 2021;:1-5. [PMID: 33584076 DOI: 10.1007/s11224-021-01731-z] [Reference Citation Analysis]
336 Tronina O, Durlik M, Orłowska I, Lorenc B, Łapiński TW, Garlicki A, Dybowska D, Zarębska-Michaluk D, Tudrujek-Zdunek M, Citko J, Janczewska E, Kaczmarczyk M, Jaroszewicz J, Krygier R, Klapaczyński J, Dobracka B, Białkowska-Warzecha J, Piekarska A, Simon K, Halota W, Pawłowska M, Tomasiewicz K, Flisiak R. Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. Ann Gastroenterol 2021;34:438-46. [PMID: 33948071 DOI: 10.20524/aog.2021.0595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
337 EASL Recommendations on Treatment of Hepatitis C Panel. Electronic address: easloffice@easloffice.eu. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues". J Hepatol 2021;74:474-5. [PMID: 33229012 DOI: 10.1016/j.jhep.2020.10.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Ridruejo E, Piñero F, Mendizabal M, Silva M; Latin American Liver Research Educational, Awareness Network (LALREAN). Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. J Viral Hepat 2021;28:446-7. [PMID: 33147362 DOI: 10.1111/jvh.13433] [Reference Citation Analysis]
339 Dai CY, Chuang WL, Yu ML. EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues. J Hepatol 2021;74:473-4. [PMID: 33223214 DOI: 10.1016/j.jhep.2020.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
340 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
341 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
342 Isfordink CJ, van de Laar TJW, Rebers SPH, Wessels E, Molenkamp R, Knoester M, Baak BC, van Nieuwkoop C, van Hoek B, Brakenhoff SM, Blokzijl H, Arends JE, van der Valk M, Schinkel J. Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infect Dis 2021;8:ofab006. [PMID: 33614815 DOI: 10.1093/ofid/ofab006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Kim BH, Park J. Antiviral Therapy in Liver Cancer. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_5] [Reference Citation Analysis]
344 Dusheiko G. Current Management of Patients with HCV Genotype 5 or 6. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_9] [Reference Citation Analysis]
345 Roche B, Coilly A, Samuel D. Management of Transplant Patients Infected with HCV. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_11] [Reference Citation Analysis]
346 Zhou K, Terrault NA. Treatment of HCV, HDV, or HIV Coinfections. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_15] [Reference Citation Analysis]
347 Kornilova EB, Hołownia-voloskova ME, Ar’kova ES, Roslik DA, Luchinin EA, Zavyalov AA. Regional experience in assessing medical technology on the example of antiviral therapy for chronic hepatitis C with direct antiviral drugs. Health Care of the Russian Federation 2020;64:318-323. [DOI: 10.46563/0044-197x-2020-64-6-318-323] [Reference Citation Analysis]
348 Kang SH, Kim MY. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care. Clin Mol Hepatol 2021;27:100-2. [PMID: 33317234 DOI: 10.3350/cmh.2020.0312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
349 Bartres C, Soy G, Forns X. Hepatitis C therapy and anticonvulsants. Gastroenterol Hepatol 2021;44:536. [PMID: 33253770 DOI: 10.1016/j.gastrohep.2020.11.003] [Reference Citation Analysis]
350 Peschel G, Grimm J, Gülow K, Müller M, Buechler C, Weigand K. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics (Basel) 2020;10:E974. [PMID: 33228201 DOI: 10.3390/diagnostics10110974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]